1.93
-6.31%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Canton Strategic Holdings
From its filings with the US Securities and Exchange Commission
Canton Strategic Holdings is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CNTN. The SEC classifies its business as finance services. In the fiscal year to 31 December 2025, it reported a net loss of $35.9m. At that date it held total assets of $519.1m and shareholders' equity of $397.9m.
November 2025, we have strengthened our liquidity and expanded our access to capital through a public offering of common stock and private placements, and by establishing a shelf registration statement and our ATM Program (as defined below).
CC’s fair-launch and incentive alignment across the network anchors the token in real-world transactions and utility over speculation.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Jan 2022
- Employees
- 12
- Website
- tharimmune.com ↗
- Head office
- 1460 BROADWAY, NEW YORK, NY, 10036
- Incorporated in
- DE
- Classification
- Finance Services
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Mark WendlandChairman of the Board, Chief Executive Officer, since 2025
- Mr. Mark ToomeyPresident
- Mr. Jacob AsburyChief Financial Officer
- Mr. Sireesh AppajosyulaChief Executive Officer of Gravitas Life Sciences, Inc., Director, since 2021$706,039
- Ms. Angela RadkowskiChief Operating Officer
- Mr. Vincent LoPrioreDirector, since 2025
- Mr. James LiddyDirector
- Mr. Clay KahlerIndependent Director
- Ms. Jill SommersIndependent Director
- Mr. Gary StetzIndependent Director
- Mr. William WileyIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tharimmune Inc's HSB-1216 targets treatment-resistant cancers including triple negative breast cancer.
- The Quatramer platform enhances HSB-1216 uptake in tumor microenvironment for better efficacy.
- Trident AI identifies biomarkers to target specific patient segments in clinical programs.
Weaknesses
- Tharimmune Inc employs only 12 full-time employees in Bridgewater, New Jersey.
- The company's pre-clinical stage limits immediate market impact and revenue generation.
- HSB-1216 is still in development without FDA approval for cancer treatment.
Opportunities
- HSB-1216 shows potential for treating epithelial carcinomas and solid tumors.
- The Trident AI platform can expand to identify new biomarkers for precision medicine.
- The biotechnology sector in the US offers growth opportunities for pre-clinical firms.
Threats
- Competition from established biotech firms in the US Health Care sector.
- Regulatory delays could impact the FDA approval timeline for HSB-1216.
- Market volatility in the biotechnology industry may affect funding and partnerships.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.